Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Sarepta told RBC patient death confirmed unrelated to Elevidys
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Investing9d
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
These projections underscore the market's confidence in Sarepta's ability to capitalize on its current momentum. Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary ...
appliedclinicaltrialsonline9d
Elevidys Shows Continued Promise in Phase III EMBARK Trial for the Treatment of Duchenne Muscular Dystrophy
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
Investing9d
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
These projections underscore the market's confidence in Sarepta's ability to capitalize on its current momentum. Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth ...
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...
Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
PMLiVE9d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
Nvidia And 2 Other High Growth Tech Stocks In The United States
Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...